A majority of B cell lymphomas-including follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL), the most common forms of non-Hodgkin lymphoma-arise from germinal center (GC) B cells. GCs are highly specialized regions within peripheral lymphoid tissues where B lymphocytes undergo rapid proliferation, somatic hypermutation (SHM), Ig class switching and differentiation to form high-affinity antibody-secreting cells during an immune response. Extensive GC B cell proliferation coupled to mutagenesis is thought to facilitate the emergence of pro-oncogenic genetic lesions that trigger lymphoma development 1 . FL arises from GC B cells that have acquired a t(14;18) translocation, presumably during earlier VDJ recombination, leading to constitutive expression of the antiapoptotic BCL2 oncogene 2 . However, this translocation is also detectable in many healthy adults who never develop the disease 2 . Additional mutations must therefore contribute to lymphomagenesis. Recent genome sequencing studies have cataloged somatic mutations that may promote GC-derived lymphomas 3, 4 . Notably, the gene for the lysine methyltransferase KMT2D (KMT2D, also called MLL2 or MLL4) has emerged as one of the most frequently mutated genes, with reported mutation frequencies ranging from 30-85% in both FLs and DLBCLs 3,4 . KMT2D is a catalytic component of the mammalian COMPASS (complex of proteins associated with Set1) complex, which facilitates transcription through mono-and dimethylation of H3K4 at enhancer regions in DNA 5-8 . The reported spectrum of KMT2D mutations in lymphoma, which includes frequent nonsense mutations upstream of the catalytic SET domain and does not appear to localize to a mutation hotspot, suggests loss of enzymatic function 3,4 . Here we define the function of KMT2D in healthy and malignant B cells.
A majority of B cell lymphomas-including follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL), the most common forms of non-Hodgkin lymphoma-arise from germinal center (GC) B cells. GCs are highly specialized regions within peripheral lymphoid tissues where B lymphocytes undergo rapid proliferation, somatic hypermutation (SHM), Ig class switching and differentiation to form high-affinity antibody-secreting cells during an immune response. Extensive GC B cell proliferation coupled to mutagenesis is thought to facilitate the emergence of pro-oncogenic genetic lesions that trigger lymphoma development 1 . FL arises from GC B cells that have acquired a t(14;18) translocation, presumably during earlier VDJ recombination, leading to constitutive expression of the antiapoptotic BCL2 oncogene 2 . However, this translocation is also detectable in many healthy adults who never develop the disease 2 . Additional mutations must therefore contribute to lymphomagenesis. Recent genome sequencing studies have cataloged somatic mutations that may promote GC-derived lymphomas 3, 4 . Notably, the gene for the lysine methyltransferase KMT2D (KMT2D, also called MLL2 or MLL4) has emerged as one of the most frequently mutated genes, with reported mutation frequencies ranging from 30-85% in both FLs and DLBCLs 3, 4 . KMT2D is a catalytic component of the mammalian COMPASS (complex of proteins associated with Set1) complex, which facilitates transcription through mono-and dimethylation of H3K4 at enhancer regions in DNA [5] [6] [7] [8] . The reported spectrum of KMT2D mutations in lymphoma, which includes frequent nonsense mutations upstream of the catalytic SET domain and does not appear to localize to a mutation hotspot, suggests loss of enzymatic function 3, 4 . Here we define the function of KMT2D in healthy and malignant B cells.
RESULTS

KMT2D deficiency promotes lymphoma development in vivo
To directly test the effect of KMT2D deficiency in the development of GC-derived lymphoma, we used the VavP-Bcl2 mouse model. In this model, the Vav promoter drives expression of the Bcl2 oncogene in all hematopoietic lineages, and this results in the development of B cell lymphomas that recapitulate key aspects of the genetics, pathology and GC origin of human FLs [9] [10] [11] . To knock down Kmt2d we transduced VavP-Bcl2 (C57BL/6) transgenic fetal liver cells (embryonic day (ED) 14.5), which are a rich source of hematopoietic progenitor cells (HPCs), with murine stem cell virus (MSCV) retroviruses that encoded a GFP reporter and either short hairpin RNAs targeting Kmt2d (shKmt2d; n = 30), an empty vector (vector; n = 37) or the Myc oncogene as a positive control for lymphomagenesis (c-Myc; n = 16). We injected an unsorted mix of transduced and untransduced HPCs into syngeneic (C57BL/6) wild-type (WT), lethally irradiated female mice and monitored the recipients for 200 d by peripheral blood smears for the emergence of lymphomas (Fig. 1a) . Knockdown of Kmt2d caused a marked acceleration of lymphomagenesis and an increase in FL penetrance from 30% to 60% (Fig. 1b) . The lymphomas expressing the Kmt2d-specific shRNA displayed a substantial enrichment of transduced cells as compared to the parental HPCs and to the HPCs transduced with empty retrovirus (Fig. 1c) . We confirmed reduction of Kmt2d mRNA levels in mouse B cells expressing the Kmt2d-specific shRNA constructs ( Fig. 1d and Supplementary Fig. 1a ).
The mice transplanted with the VavP-Bcl2-shKmt2d HPCs showed significant splenomegaly, and the lymphomas were marked by pathognomonic follicular expansion of neoplastic B220 + B lymphocytes that showed positive staining with peanut agglutinin (PNA) and had low Ki67 staining indicating slow proliferation like human FLs (Fig. 1e) . The PNA-positive staining of the B cells and their localization within follicular structures are indicative of their germinal center origin (Fig. 1f) . Compared to the lymphomas arising in control animals (recipients of VavP-Bcl2 HPCs expressing the empty vector), the Kmt2d-deficient tumors revealed a greater expansion of neoplastic B220 + PNA + B cells and an advanced destruction of the underlying splenic architecture with invasion of the red pulp in nodular, and sometimes diffuse, patterns (Fig. 1f) . Kmt2d-deficient tumors were composed of a greater number of larger, centroblast-like B cells (Supplementary Fig. 1c ) and had more prominent extranodal infiltration into the lung, liver and kidneys ( Supplementary Fig. 1d and data not shown). Immunophenotyping showed a similar composition of cells in control and Kmt2d-deficient lymphomas, with neoplastic B cells expressing B220, CD19, IgM, IgD and the GC marker GL7 HPCs transduced with MSCV-GFP retrovirus (black, n = 37), MSCV-GFP encoding shRNAs against Kmt2d (red, n = 30) or MSCV-GFP encoding c-Myc (gray, n = 16). Statistical significance of survival difference was determined by the log-rank test: shKmt2d versus vector, P = 0.03; c-Myc versus vector, P < 0.001). (c) Mice were sacrificed 5 months after injection, and splenic lymphoma cells of mice that had been injected with VavP-Bcl2 HPCs (transduced with retrovirus encoding either GFP only or coexpressing one of two independent Kmt2d-specific shRNAs (shKmt2d#1 and shKmt2d#2)) were compared by flow cytometry to the same VavP-Bcl2 HPCs before injection. (d) Recipient mice were sacrificed 5 months after HPC injection, and Kmt2d mRNA levels from MACS-sorted B220 + lymphoma B cells were quantified by qRT-PCR (vector, n = 4; shKmt2d#1, n = 5). Values correspond to average ± s.d. (e) Spleen weights (normalized to body weight) of the indicated recipient mice that were killed 5 months after HPC injection (vector, n = 9; shKmt2d#1, n = 11; c-Myc n = 5). Representative images of spleens are shown on the right. Scale bars represent 0.5 cm. Values correspond to average ± s.d. Statistical significance in d,e was determined by the two-tailed Student's t-test, *P < 0.05, ***P < 0.001. (f) Upon sacrifice, tissue was extracted from recipient mice and stained with H&E and antibodies specific for B220 and Ki67. Tissues were also stained with PNA to confirm GC origin and TUNEL to analyze apoptosis. Scale bars, 400 µm. (g) Representative images of flow cytometry analysis for the cellular composition of whole spleens from recipient mice that were sacrificed 5 months after injection with HPCs. Four tumors of each genotype were analyzed. npg (Fig. 1g, Supplementary Fig. 1b and Supplementary Table 1) . PCR analysis of the immunoglobulin light chain (IgL) locus indicated clonal disease (Supplementary Fig. 1e ), and sequence analysis of the VDJH4 variable region showed evidence of SHM ( Supplementary  Fig. 1f ). Hence, Kmt2d deficiency cooperates with Bcl2 to promote the development of high-grade, GC-derived FLs. Next we analyzed the potential tumor suppressor function of KMT2D in the absence of any cooperating genetic lesions. We crossed Kmt2d conditional knockout mice (Kmt2d fl/fl ) 7 with a CD19-Cre strain to induce Kmt2d deletion in CD19 + early B cells. The majority (58%) of the Kmt2d fl/fl × CD19-Cre mice (herein referred to as Kmt2d −/− ) became moribund with a survival of 338 d (Supplementary Fig. 1g ). Pathology indicated that the Kmt2d −/− B cell lymphomas in spleens and lymph nodes arose from a pre-GC B cell and were composed of monotonous, atypical B lymphocytes with a high proliferative index (>90% Ki67 + ) and abundant numbers of apoptotic cells, as assayed by TUNEL staining (Supplementary Fig. 1h ). Flow cytometry analysis of these tumors revealed the presence of CD19 + B220 + IgM + B cells that often express immunoglobulin kappa (Igκ) or lambda (Igλ) light chains and that have variable expression of IgD and the plasmacytic marker CD138 (Supplementary Fig. 1i and Supplementary Table 1) . Genomic analyses of the immunoglobulin locus in these lymphoma cells indicated an oligoclonal origin from cells that had undergone V(D)J recombination at the immunoglobulin heavy chain (IgH) and Igκ loci (Supplementary Fig. 1k,l) . However, the lymphoma cells did not undergo class switch recombination (CSR), as they retained the unrearranged IgH constant region (Supplementary Fig. 1m ). They also showed no evidence of SHM at the IgH locus ( Supplementary  Fig. 1n ) and lacked expression of markers for mouse GC B cells (PNA; Supplementary Fig. 1h ). Although the mouse tumors may not directly resemble human lymphomas, these results indicate that Kmt2d acts as a tumor suppressor in B lymphocytes and that this contrasts with its oncogenic function in the myeloid lineage 12 .
KMT2D mutations are typically seen in lymphomas that originate from GC B cells that are exposed to the genotoxic activity of the GC-specific enzyme activation-induced cytidine deaminase (AID). Therefore, we tested whether the genomic instability caused by AID would synergize with the Kmt2d deficiency to promote lymphoma development in vivo. We crossed the Kmt2d −/− mice to animals overexpressing AID (encoded by Aicda; referred to here as ' AID-Tg' mice) and observed a further acceleration of lymphoma onset (Supplementary Fig. 1g ). The Kmt2d −/− × AID-Tg tumors were more aggressive than Kmt2d −/− tumors and showed extensive dissemination into solid organs and complete effacement of the splenic architecture by diffuse proliferation of large atypical B220 + B cells with monotypic expression of IgL light chain and very high proliferative fraction (Ki67 positivity >90%). Neoplastic cells were focally positive for CD138 and had intracytoplasmic accumulation of immunoglobulins, suggesting plasmacytic differentiation ( Supplementary Fig. 1i,j) . These tumors were oligoclonal and, in contrast to the tumors arising in Kmt2d −/− mice, showed AID-induced CSR and SHM and were PNA − (Supplementary Fig. 1k-n) . Hence, AID-induced genomic instability, a hallmark feature of the mutagenic GC environment, cooperates with Kmt2d deficiency in lymphomagenesis.
KMT2D deficiency affects physiological B cell behavior
Heritable nonsense mutations in KMT2D are a major cause of the rare congenital Kabuki syndrome (also known as Kabuki makeup or Niikawa-Kuroki syndrome). The syndrome is named for its typical facial features and often comprises a mild immune defect with decreased production of class-switched antibodies by B cells and a propensity for ear infections; a possible link to tumor development has not been clearly established 13 . To examine how KMT2D deficiency affects normal B cells, we first analyzed KMT2D expression using RNA-seq in purified mature B cell subsets isolated from human tonsils. KMT2D expression levels were similar in naive, centroblast, centrocyte and memory B cells, whereas they were reduced in plasma B cells, suggesting a functional role for KMT2D before terminal B cell differentiation (Supplementary Fig. 2a ). Next we examined the effect of KMT2D knock down on GC formation using a transplantation model with WT HPCs transduced with retroviruses containing either empty vector (as a control) or Kmt2d-specific shRNA, followed by immunization with sheep red blood cells (SRBC) (Fig. 2a) . In control mice, all of the GCs resolved by week 16, as indicated by loss of PNA and Ki67 staining. In contrast, Kmt2d-knockdown mice showed persistent GCs beyond week 16 that consisted of B cells with high PNA and Ki67 staining (Fig. 2b,c) . To determine how complete genetic Kmt2d inactivation affects mature B cell populations, we examined unimmunized 4-to 5-month-old Kmt2d −/− mice (before lymphoma onset). Flow cytometric analysis of splenocytes harvested from WT and Kmt2d −/− mice indicated there were equal numbers of total B220 + B cells, intermediate plasmablasts (IPCs; B220 + CD138 + ) and plasma cells (B220 − CD138 + ) in both sets of mice ( Supplementary  Fig. 2b,c) . We observed a twofold increase in the number of transitional B cells (B220 + CD21 − CD23 − ) and a trend toward elevated numbers of GC B cells (B220 + GL7 + CD95 + ) in the Kmt2d −/− mice ( Supplementary Fig. 2b-e) . To determine the impact of Kmt2d deletion on GC formation and differentiation, we immunized mice with NP-CGG (4-hydroxy-3-nitrophenylacetyl chicken gamma globulin) to induce GC formation and analyzed splenocytes harvested from WT and Kmt2d −/− mice 6 d after immunization. Flow cytometric analysis indicated a modest decrease in follicular B cells (FO; B220 + CD23 + CD21 lo ), a trend toward decreased numbers of plasmablasts and increased numbers of transitional B cells (TR) and, most notably, a significant threefold increase in the number of GC B cells in Kmt2d −/− splenocytes, as compared to those from WT mice (Fig. 2d,e) . These results indicate that Kmt2d loss results in an expansion of GC B cells (which represent the cell type from which DLBCLs and FLs arise in humans) after immunization.
To determine whether Kmt2d loss affects B cell antibody production, we measured serum IgM and IgG1 levels by ELISA in WT and Kmt2d −/− mice. Results showed that IgM antibody levels were similar for both groups of mice under basal conditions, and although the wild-type mice showed the expected increase in IgG1 levels following NP-CGG immunization, Kmt2d −/− mice had decreased IgG1 levels, indicating a class switch defect (Fig. 2f) . Consistent with these in vivo findings, we also observed a defect in CSR to IgG1 in Kmt2d-deficient B cells after in vitro stimulation with lipopolysaccharide (LPS), CD180-specific antibody and interleukin-4 (IL-4), as indicated by reduced surface IgG1 expression on the Kmt2d −/− B cells (Fig. 2g-i) . Hence, KMT2D loss affects B cell differentiation and impedes the B cell immune response in a manner consistent with the mild immune defect associated with Kabuki syndrome.
Consequences of KMT2D mutations in human lymphomas
To explore the effects of KMT2D mutations on clinical behavior, we established the KMT2D mutation status in a cohort of 104 human FL specimens. We detected KMT2D mutations in nearly 40% of samples but did not find an apparent hotspot (Fig. 3a,b and Supplementary Table 2 ). In these FLs, 38 of the 104 samples had npg KMT2D mutations, with four being homozygous. Of a total of 49 KMT2D mutations, 36 were nonsense, 12 were missense and one was a frameshift mutation. KMT2D mutations in FL were not significantly associated with FL grade (Supplementary Fig. 3a) .
Next we analyzed KMT2D status in a cohort of 347 newly diagnosed, clinically annotated DLBCL cases that were all treated with rituximab (R) plus a combination of cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP)-referred to here as R-CHOP-at the BC Cancer Agency (Vancouver) and that were classified as GC B cell (GCB) or activated B cell (ABC) subtype by gene expression profiling. The cases were selected on the basis of the following criteria: individuals were 16 years of age or older with histologically confirmed de novo DLBCL according to the 2008 World Health Organization (WHO) classification, and DNA extracted from fresh-frozen biopsy material (tumor content > 30%) was available. The overall mutation frequency was similar to our FL cohort; however, we noticed a higher prevalence of nonsense mutations in the GCB subtype (17.6%) than in the ABC subtype (8.4%) ( Supplementary  Fig. 3b ). KMT2D mutations were not significantly linked to overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS) or time to progression (TTP) (Fig. 3c,d, Supplementary Fig. 3c,d and Supplementary Table 2 ; see Online Methods for further details). The lack of correlation may indicate no effect of this specific treatment, or it may reflect alternate changes in tumors with wild-type KMT2D that equally affect outcomes. 
npg
KMT2D controls a common set of genes in mouse and human FLs Next we investigated the transcriptional changes related to KMT2D mutation status by RNA-seq on seven human FL specimens with KMT2D nonsense mutations and 12 with wild-type KMT2D. As expected, the most differentially expressed genes in FLs with nonsense mutation-containing KMT2D were skewed toward gene downregulation, such that among the top 100 genes 70% were decreased, whereas that fraction decreased to 55% when 500 genes were included ( Fig. 3e and Supplementary Fig. 3e,f) . Similarly, RNA-seq on mouse B220 + cells purified by magnetic cell sorting (MACS) from Kmt2d-knockdown (n = 5) and control lymphomas (n = 4) revealed that differentially expressed genes in Kmt2d-deficient lymphomas were skewed toward gene downregulation, further supporting the established role of Kmt2d as an activator of gene expression ( Fig. 3f and Supplementary Fig. 3g,h ). Moreover, genes that were downregulated in the mouse Kmt2d-deficient lymphomas were highly enriched among genes that were downregulated in human KMT2D mutant specimens and vice versa (Fig. 3g,h and Supplementary Table 3) . By contrast, there was no enrichment among the upregulated genes (data not shown). This suggests the downregulation of a conserved gene expression signature in human and mouse KMT2D-deficient lymphomas. To further explore these signatures, we examined the leading-edge genes that drive this reciprocal relationship for potential B cell functions that are perturbed by KMT2D-inactivating mutations (Supplementary Table 4 ). The analysis revealed an enrichment for genes implicated in the immediate early response to antigen and growth factor stimulation, IL-6, IL-10, RAS and tumor necrosis factor (TNF) signaling pathways ( Fig. 3i and Supplementary Table 4 ) and for plasma cell differentiation-related genes ( Supplementary  Fig. 3i,j) . Hence in human and mouse FLs, KMT2D controls a common set of genes related to immune signaling and B cell differentiation pathways.
To assess how KMT2D depletion contributes to transcriptional regulation, we measured H3K4 mono-and dimethylation (H3K4me1
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Immediate-early genes C o n t r o l g e n e s and H3K4me2, respectively) in Kmt2d-deficient and control lymphomas. Using an antibody that specifically recognizes H3K4me1 and H3K4me2 on DNA, we performed ChIP-seq on purified B220 + mouse lymphoma cells (n = 3 for both empty vector-containing and shKmt2d-containing VavP-Bcl2 cells). First, analysis of ChIP-seq data for H3K4me1 and H3K4me2 abundance did not reveal a global loss of the marks genome wide (Fig. 4a) . We confirmed this observation with immunoblots for H3K4me1, H3K4me2 and trimethylated H3K4 (H3K4me3) on lysates from sorted B220 + mouse Kmt2d-knockdown lymphoma cells (Supplementary Fig. 4a,b) and nonmalignant B220 + cells from WT and Kmt2d −/− mice ( Supplementary Fig.  4c,d ). By contrast, we observed focal depletion of the H3K4me1 and H3K4me2 marks at a subset of genomic sites in the mouse VavP-Bcl2-shKmt2d lymphomas. Specifically, H3K4me1 and H3K4me2 depletion was significantly more pronounced at putative enhancers as compared to that in promoter elements ( Fig. 4b and Supplementary Table 5 ). Using gene set enrichment analyses (GSEA) we found that the genes associated with significant H3K4me1 and H3K4me2 depletion in enhancers and promoters (≥25% read density reduction) were enriched among downregulated genes in both mouse and human KMT2D-deficient lymphomas (Fig. 4c,d and Supplementary  Fig. 4e,f) . The leading-edge genes (Supplementary Table 4 ) driving this association were enriched for target genes induced by CD40, NF-κB, IL-6, IL-10, LPS, TGF-β and TNF-α (Fig. 4e,  Supplementary Fig. 4g and Supplementary 16 , Asxl1 and Arid1A (Fig. 4f, Supplementary Fig. 4h ).
Next we analyzed H3K4me1 and H3K4me2 abundance in human lymphoma cell lines that were either wild type (OCI-LY7, HT, DOHH2 and SU-DHL4) or mutant (OCI-LY1, OCI-LY18, Toledo and Karpas422) for KMT2D. As in the mouse lymphomas, measurements of global H3K4 methylation by immunoblotting and mass spectrometry showed no differences between the lymphoma lines with WT and mutant KMT2D (Supplementary Fig. 5a-c) . Consistent with the results in the mouse lymphomas, H3K4me1 and H3K4me2 ChIP-Seq on human lymphoma cells containing either WT (OCI-LY7) or mutant (OCI-LY1) KMT2D showed a focal defect that was limited to a subset of H3K4me1 and H3K4me2 sites, and ranking based on the extent of H3K4me1 and H3K4me2 depletion confirmed a predominant effect on enhancers similar to those observed in the experiments in mouse lymphoma cells ( Fig. 5a and Supplementary  Table 5 ). However, initial analyses for the enrichment of the loss of H3K4me1 and H3K4me2 among genes that were downregulated in human FLs with mutant KMT2D did not show the expected level of enrichment ( Fig. 5b and Supplementary Table 6 ). This indicated that we needed to more accurately define the direct KMT2D target genes in human lymphoma cells. To measure KMT2D binding directly we performed ChIP-seq in OCI-LY7 and OCI-LY1 cells using a validated antibody against KMT2D. Similarly to previous studies, we identified ~24,000 KMT2D-binding sites; 32% were associated within transcriptional start sites (TSS) and the others were distributed to locations that were intragenic or upstream or downstream of genes in the OCI-LY7 cells (Fig. 5c) (ref. 5) . Of note, genes in OCI-LY7 cells that were bound directly by KMT2D and that had a loss of H3K4me1 and H3K4me2 were also highly enriched among the downregulated genes that were identified in human FL subjects with KMT2D mutations (Fig. 5d and Supplementary Table 6 ). Once again these KMT2D target genes were associated with immune signaling pathways including those involving CD40, IL-6, IL-10, NF-κB, IRF4 and others ( Fig. 5e and Supplementary Table 4) . Consistent with the analysis of the mouse lymphomas, these genes included the lymphoid tumor suppressors TNFAIP3 (A20) and SOCS3, which showed consistent changes in KMT2D binding and H3K4 methylation in cells with WT (OCI-LY7) and mutant (OCI-LY1) KMT2D ( Fig. 5f and Supplementary Fig. 5d ). Fig. 6a,b) . Next we tested three shRNAs for KMT2D knockdown (shKMT2D #1-3) and used qRT-PCR to measure effects on the expression of candidate target genes. We found a marked loss of expression for the indicated KMT2D targets in both isogenic, paired human cell lines and also in purified mouse lymphoma B220 + B cells ( Fig. 6a and Supplementary Fig. 6c-e) . For further confirmation of (Fig. 6b) . Hence, KMT2D targets the regulatory regions of several tumor suppressor genes that control B cell signaling pathways.
Next we probed how KMT2D loss in human lymphoma cells affected the specific functions of key KMT2D targets. We used isogenic pairs of KMT2D-proficient and KMT2D-deficient human lymphoma cell lines using shRNA knockdown. We identified SOCS3, a negative regulator of STAT3 signaling, as a KMT2D target. Accordingly, we found a reduction of SOCS3 protein levels and an augmentation in the JAK-STAT response to IL-21 stimulation in the KMT2D-deficient cells as compared to those in the isogenic control OCI-LY7 cells (Fig. 6c) . Among the KMT2D target genes we also identified key Fold change Values correspond to the average of three replicates ± s.d.; two-tailed Student's t-test was used to determine statistical significance; *P < 0.05, **P < 0.01, ***P < 0.001. (b) qChIP analysis for H3K4me1-H3K4me2 occupancy loss in enhancer regions of the specified KMT2D target genes after KMT2D knockdown in OCI-LY7 cells. A genomic region (TNS4) with no KMT2D binding and H3K4me1-H3K4me2 was used as a negative control. Values correspond to mean percentage of input enrichment ± s.d. of triplicate qPCR reactions of a single replicate. Two-tailed Student's t-test was used to determine statistical significance; ***P < 0.001. Data correspond to one representative assay from a total of 2 or 3 independent assays. (c) Immunoblot of the indicated proteins in vector-or shKMT2D-expressing OCI-LY7 cells upon 48 h of IL-21 stimulation. Actin was used as a loading control and was quantitated using ImageJ. (d) TNFAIP3 mRNA levels in OCI-LY7 and SU-DHL4 cells transduced with vector or shKMT2D after 48 h of stimulation with antibodies to CD40 and IgM. Values correspond to the average of three experimental replicates ± s.d., and statistical significance was determined by the two-tailed Student's t-test; **P < 0.01, ***P < 0.001. (e) Flow cytometric analysis of cell death induced by treatment with antibodies to CD40 and IgM in OCI-LY7 lymphoma cells that were transduced with a lentivirus containing vector alone or shKMT2D. (f) Proliferation of OCI-LY7 (KMT2D wt ) and OCI-LY1 (KMT2D mut ) lymphoma cell lines upon stimulation with antibodies to CD40 alone or to both CD40 and IgM. Values correspond to the average of three experimental replicates relative to day 0 ± s.d. Two-tailed Student's t-test was used to determine statistical significance; *P < 0.05, **P < 0.01. (g,h) Viability assays in lymphoma cell lines upon stimulation with CD40-specific antibody for 96 h. Representative plots (g) and quantification (h), as analyzed by flow cytometry using annexin V and DAPI exclusion. Bars correspond to the average of three experimental replicates ± s.d. Two-tailed Student's t-test was used to determine statistical significance. *P < 0.05, **P < 0.01. (i) TNFAIP3 (A20) (left) and NFKBIZ (right) mRNA levels in WT KMT2D-containing OCI-LY7, HT and SU-DHL4 and mutant KMT2D-containing OCI-LY1 and NU-DUL1 lymphoma cell lines upon stimulation with antibodies to CD40 alone or to both CD40 and IgM (24 h). Bars represent the mean of three biological replicates (two biological replicates for NU-DUL1 treated with antibodies to CD40 + IgM; white bar) ± s.d. Two-tailed Student's t-test was used to determine statistical significance; *P < 0.05, **P < 0.01. Red labels represent KMT2D-mutant cell lines and black labels represent cell lines with WT KMT2D.
npg signaling molecules involved in the CD40, B cell receptor (BCR) and Toll-like receptor (TLR) pathways (such as TRAF3, TNFAIP3, MAPK3K8 and DUSP1). Transcriptional expression of many of these target genes, including TNFAIP3, is dependent on CD40 and BCR signal activation (refs. 18,19 ). Therefore, we tested whether loss of KMT2D in the wild-type KMT2D-containing cell lines OCI-LY7 and SU-DHL4 affected the induction of KMT2D target genes when the cells were stimulated with antibodies to CD40 and IgM. Analysis by qRT-PCR showed that the induction of TNFAIP3 was greatly diminished in both cell lines after KMT2D knockdown (Fig. 6d) . CD40 signaling has also been shown to be pro-apoptotic in a panel of DLBCL cell lines 20 . Therefore we tested if KMT2D knockdown could protect OCI-LY7 cells from apoptosis induced by CD40 signaling and found that, after treatment with antibodies to CD40 and IgM, OCI-LY7 cells harboring the KMT2D-specific shRNA showed reduced cell death induction, as measured by annexin V and DAPI staining (Fig. 6e) . We made analogous observations when comparing panels of lymphoma cell lines with WT (OCI-LY7, HT, SU-DHL4) or mutant (OCI-LY1, OCI-LY18, NU-DUL1) KMT2D. For example, OCI-LY7, HT and SU-DHL4 cells (which contain wild-type KMT2D) showed greater growth inhibition than cell lines OCI-LY1, OCI-LY18 and NU-DUL1 (which contain mutant KMT2D) upon treatment with antibody to CD40 alone or in combination with that to IgM ( Fig. 6f and Supplementary Fig. 6g) . Similarly, viability assays showed that cells with wild-type KMT2D were more sensitive than cells with mutant KMT2D to CD40 stimulation and had increased levels of apoptosis, as measured by annexin V and DAPI staining (Fig. 6g,h ). These differences were not caused by differential CD40 receptor expression, as only OCI-LY18 does not express the CD40 receptor and was not affected by treatment with the CD40-specific antibody (Supplementary Fig. 6f ). Analysis of target gene expression showed that in KMT2D-mutant cell lines there was an overall attenuated transcriptional response for important KMT2D targets such as the tumor suppressor genes TNFAIP3 (A20), NFKBIZ, FAS and DUSP1 (Fig. 6i and Supplementary Fig. 6h ). Hence, KMT2D deficiency affects key effects of BCR, CD40 and JAK-STAT signaling in lymphoma B cells.
DISCUSSION
Our results establish the tumor suppressor function of KMT2D in germinal center B cells. The H3K4 methyltransferase KMT2D is one of the most frequently mutated genes in DLBCL and FL 3, 4 , and we show that it controls the expression of multiple key regulators of the CD40, TLR and BCR signaling pathways (Supplementary Fig. 7 ). Bona fide KMT2D target genes include lymphoid tumor suppressor genes such as TNFAIP3, SOCS3, SGK1, TRAF3, TNFRSF14 and ARID1A [14] [15] [16] . KMT2D also contributes to the normal B cell response, and KMT2D-deficient mice show an abnormal persistence of germinal centers, a defect in class switch recombination and reduced antibody production reminiscent of the reported immune defect seen in the heritable Kabuki syndrome, which has been most often linked to KMT2D mutations. Collectively these data suggest that KMT2D somatic mutations may drive GC expansion due to enhanced proliferation and impaired terminal differentiation of B cells and to loss of H3K4 mono-and dimethylation at key B cell enhancer regions and some promoters. Our results are consistent with genomic evidence indicating that KMT2D mutations are early lesions in GC lymphomas 3, 4 . Notably, even in the absence of Bcl2 activation, KMT2D deficiency is sufficient to trigger B cell malignancy in mice. Clinically, KMT2D mutations are not associated with the outcome of R-CHOP chemotherapy in DLBCL. 21 . Similarly, inhibition of H3K4 demethylase activities, such as those of JARID1 and LSD1, may be able to reverse some of the epigenetic changes seen in KMT2D-deficient lymphomas 22 .
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Measurement of KMT2D mRNA expression in human B cells. The human tonsil and bone marrow samples were obtained in Pamplona (Spain) at the Clinica Universidad de Navarra and the obtention of these samples was approved by the ethical committee of Clinica Universidad de Navarra (Spain). Cells from tonsils and bone marrow were immunophenotyped using an eight-color antibody combination (CD20-Pacific Blue (PB), CD45-Oranje Chrome 515 (OC515), CD38-fluorescein isothiocyanate (FITC), CXCR4-phycoerythrin (PE), CD3-peridinin chlorophyll protein-cyanin 5.5 (PerCP-Cy5.5), CD10-PE-cyanin 7 (PE-Cy7), CD27-allophycocyanin (APC) and CD44-APCH7) aimed at the identification and high-purity (≥97%) FACS-sorting (FACSAria II, Becton Dickinson Biosciences, San Jose, CA) of the following B cell (CD3 − CD20 + CD45 + ) subsets (after careful exclusion of CD3 + CD20 − CD45 + T cells): naive B cells (CD10 − CD44 + CD27 − CD38 − ), germinal center (CD10 + CD44 lo CD38 + ) centrocytes (CXCR4 − ) and centroblasts (CXCR4 + ), memory B cells (CD10 − CD27 + CD44 + ) and new-born plasmablasts (CD10 − CD27 hi CD38 hi CD44 hi ). The strand-specific RNA-seq was performed in naive B cells (n = 5 samples), centroblasts (n = 7), centrocytes (n = 7), memory cells (n = 8), tonsilar plasma B cells (n = 5) and purified plasma B cells from bone marrow of healthy donors (n = 3).
Characterization of human FL samples. The Institutional Review Board (IRB) of Weill Cornell Medical College (IRB#0107004999) approved the study protocol. The specimens were derived from excess diagnostic materials that were banked in the lymphoma repository. A waiver of informed consent has been obtained for this retrospective study. The IRB-approved protocol permitted association of these specimens with a particular individual, allowing review of the medical records for the minimum information necessary to complete the study. All of the data that were provided to investigators were stripped of protected health information. Sample preparation. Frozen single-cell suspensions of individual tumor samples were first thawed in a 37 °C water bath and then resuspended in RPMI + 10% FBS and incubated in an incubator (37 °C and 5% CO 2 ) for 1 h. Half of the sample was used to isolate B cells by using EasySep Human B Cell Enrichment Kit (STEMCELL Technologies, Vancouver, Canada), and the other half was used to isolate T cells with Easy Sep Human T Cell Isolation Kit. DNA was extracted from isolated cell populations by using PureLink Genomic DNA kit (Life Technologies, Grand Island, NY). Total RNA was extracted using the Qiagen RNeasy Mini Kit (Valencia, CA). The quantity of DNA and RNA samples was measured by a Qubit Fluorometer (Life Technologies, Grand Island, NY), and the quality of DNA and RNA samples was assessed by a bioanalyzer (Agilent Technologies, Santa Clara, CA).
Exome sequencing. For each tumor sample and the respective T cell control sample, 3 µg of high-molecular-weight genomic DNA was used to prepare exome sequencing libraries using the Aglient SureSelect XT ATP6AP1, B2M, BCL2, BCL6, BTG1, BTG2,  CARD11, CD79B, CREBBP, EB1, EEF1A1, EP300, EZH2, GNA13, HIST1H1B,  HIST1H1C, HVCN1, IRF4, IRF8, KLHL6, KMT2D, MEF2B, MYD88, PCGF5,  PDS5A, PIM1, POU2F2, PRDM1, SGK1, STAT6, SZT2, TBL1XR1, TNFAIP3,  TP53 and XPOT. The entire coding regions of this set of genes were targeted by overlapping PCR amplicons averaging 200 bp. DNA (200 ng) was first sheared to around 3 kb by using a Covaris S220 Focused ultrasonicator (Woburn, MA) and then merged with primer pairs in a picoliter-droplet format on a Raindance ThunderStorm system. Targeted regions were amplified with the addition of specific tailed primers. A second round of PCR was performed to add indexed adaptor sequences for Illumina sequencing. Final indexed products from 48 samples were multiplexed together and sequenced on one entire lane of flow cell on Illumina HiSeq 2500 by using the fast mode setting. Sequence information of 100 bp on each end of the library fragment (PE100) was collected.
Discovery of single-nucleotide variants (SNV). Sequencing reads were aligned to human genome assembly GRCh37/hg19 using the BWA aligner 23 . After filtering duplicated paired reads, variants were detected as previously described [24] [25] [26] . Novel coding region SNVs were defined as those that were not present in SNP132. These SNVs were then further filtered by sequencing depth (≥20×) and variant percentage (≥25%). To obtain the list of somatic mutations in each tumor sample, we compared the variant ratio of each novel coding SNV between tumor B cells and their respective control T cells and estimated the statistical significance of the difference using a chi-squared test, corrected with multiple hypothesis testing (Benjamini-Hochberg corrected P < 0.1).
Characterization of DLBCL samples. We analyzed 347 newly diagnosed DLBCL cases, in which individuals were treated with R-CHOP (given with curative intent) at the BC Cancer Agency (Vancouver). Subject sample use was approved by the University of British Columbia, British Columbia Cancer Agency, Research Ethics Board (REB #H13-01478). The cases were selected on the basis of the following criteria: 16 years of age or older; histologically confirmed de novo DLBCL according to the 2008 WHO classification; available DNA extracted from fresh-frozen biopsy material (tumor content >30%). All cases were centrally classified by A.M. and R.D.G., who were blinded for sample identity to determine the diagnosis. Individuals were excluded if they were younger than 16 years old and had DLBCL that was not de novo DLBCL (primary mediastinal large B cell lymphoma, primary central nervous system lymphoma and a previous diagnosis of an indolent lymphoproliferative disorder) and positive HIV serology.
Targeted resequencing in DLBCL samples. Targeted resequencing of the coding exons of KMT2D in 347 DLBCL cases was performed using a Truseq Custom Amplicon assay (Illumina) and libraries were run on the MiSeq (Illumina). Mutation calling was done with Mutascope pipeline. Cell-of-origin (COO) classification was available in 331 cases according to gene expression profiling by the Lymph2Cx assay using the NanoString platform 27 in 299 subjects, as well as Hans algorithm 28 in 32 cases with low tumor content. 194 cases were assigned to GCB subtype, 107 cases to the ABC (non-GCB) subtype and 30 were unclassifiable.
Correlation between KMT2D mutation status with disease progression and survival. Baseline characteristics were compared between the groups with KMT2D mutation type using the chi-squared test.
We measured the endpoints from the time of the initial pathologic diagnosis to the following events: overall survival (OS; the date of death from any cause or to the last follow-up); progression-free survival (PFS; the date of progression, relapse or death from any cause); disease-specific survival (DSS; the date from lymphoma or acute treatment toxicity) and time-to-progression (TTP; the date of progression, relapse or death from lymphoma or acute treatment toxicity). OS, PFS, DSS and TTP were estimated using the Kaplan-Meier method and differences in outcome between groups were assessed using the log-rank test. Two-sided P < 0.05 was considered significant. Data were analyzed using SPSS software (SPSS version 14.0; SPSS Inc., IL).
Generation of mice.
Kmt2d fl/fl mice were previously described 7 and here we bred them with CD19-Cre mice (Jackson no. 006785) where Cre is expressed from the pre-B cell stage and removes exons 16-19 of Kmt2d causing an open reading frame shift that creates a stop codon in exon 20. Kmt2d fl/fl × CD19-Cre mice were maintained in a mixed C57BL/6; 129 background. Mice were monitored for tumor formation once a week for the first 4 months and every day after then. All mice were housed in the Frederick National Laboratory and treated with procedures approved by the US National Institutes of Health (NIH) Animal Care and Use Committee.
The VavP-Bcl2 mouse model of FL 9 was adapted to the adoptive transfer approach using retrovirally transduced HPCs. HPC isolation and transduction were performed as in ref. 29 . 8-to 10-week-old lethally irradiated (4.5Gy twice) C57BL/6 females were used as recipients for all transplantation experiments. shRNAs to mouse Kmt2d were designed using 'Designer of Small Interfering RNA' (DSIR, http://biodev.extra.cea.fr/DSIR/) and are based on MSCV 30 : shKmt2d #1 (mouse), GACTGGTCTAGCCGATGTAAA and shKmt2d #2 (mouse), TGAATCTTTATCTTCAGCAGG.
Mouse B220 + tumor sample preparation. B220 + cells were purified from mouse lymphoma tumors by immunomagnetic enrichment with CD45R (B220) npg microbeads (Miltenyi Biotech). RNA extraction was performed using TRIzol (Ambion) using the manufacturer's protocol.
Histology. Mouse tissues were fixed overnight in formalin, embedded in paraffin blocks and sectioned. Tissue sections were stained with hematoxilin and eosin (H&E) or with Ki67, TUNEL, B220 or PNA following standard procedures 31, 32 .
Flow cytometric analysis. VavP-Bcl2 tumors. Tumor cell suspensions of representative tumors for each genotype were stained as described 29 . The antibodies used were B220 (CD45R; BD Pharmingen, #553092) or IgG1 (BD Pharmingen #560089), which were conjugated with APC, and B220 (CD45R; BD Pharmingen, #553090), CD19 (BD Pharmingen, # 557399), IgM (Pharmingen, #553409), Thy1 (CD90; Cedarlane, #CL8610PE), CD8 (Pharmingen, #553032), Sca-1 (Pharmingen, #553108), IgD (BD Pharmingen #558597) and GL7 (BD Pharmingen #561530), which were conjugated with phycoerythrin. Analysis was performed with a BD LSRFortessa cell analyzer and FlowJo software (Tree Star). DLBCL cell lines. CD40R expression on DLBCL cell lines was measured using FITC-conjugated anti-CD40 (BD clone C53 #B555588). DLBCL cell line viability was measured by APC-conjugated anti-annexin V (BD #B550474) and DAPI exclusion. Data were acquired on MacsQuant flow cytometer (Miltenyi Biotec) and analyzed using FlowJo software package (TreeStar).
IgVH rearrangement analysis. PCR to evaluate IgVH rearrangements was performed on cDNA of VavP-Bcl2 lymphoma cells with a set of a forward primer that anneal to the framework region of the most abundantly used IgVL gene families and a reverse primer located in the Jλ1,3 gene segment (IgL-Vλ1: GC CATTTCCCCAGGCTGTTGTGACTCAGG and IgL-Jλ1,3: ACTCACCTAGG ACAGTCAGCTTGGTTCC) 33 . Somatic hypermutation. The genomic sequences from VH to the intron downstream of JH4 were PCR-amplified from tumor DNA using degenerate forward primers for the different VH families 34 and a reverse primer (5′-AGGCTCTGAGATCCCTAGACAG-3′) (ref. 35 ) downstream of JH4. Proofreading polymerase (Phusion High Fidelity, NEB) was used for amplification with previously published PCR conditions 34 . Amplification products were isolated from agarose gels and submitted to Sanger sequencing. Sequences were compared with reference and mutation rate calculated using IMGT/V-QUEST 36 and UCSC BLAT. PCR amplification and sequencing was repeated two or three times for each sample. As a negative and a positive control, DNA extracted from mouse embryonic fibroblasts (MEFS) and Igκ-AID B cells, respectively, were used in parallel (data not shown).
Class switch recombination (CSR) in
Characterization of mouse B cell differentiation and antibody production.
Germinal center assessment in mice. HPCs from C57BL/6 mice were retrovirally transduced with empty vector or shKmt2d and adoptive transfer approach was performed in 2-month-old C57BL/6 females irradiated with 4.5Gy (n = 3 or 4 per group). After 4 and 7 weeks after injection of HPCs, females were immunized intraperitoneally with 0.5 ml of 2% sheep red blood cell (SRBC) suspension in PBS (Cocalico Biologicals). Nine weeks later spleens were collected for histology and immunohistochemistry analysis. Ki67-positive cells were quantified using Metamorph software.
For analysis of the formation of GCs in Km2d −/− mice, four mice for each genotype (1.5-to 2-month-old, wild-type: 2 males and 2 females; Kmt2d −/− mice: 3 males and 1 female) were immunized intraperitoneally with 100 µg of NP21-CGG (Biosearch Technologies) in Imject alum (Pierce). On day 6 after immunization, splenocytes were harvested and B cell populations were analyzed by flow cytometry as above (see Characterization of B cell populations in Kmt2d −/− mice).
ELISA analysis of NP-specific antibody production. Serum from NP-CGGimmunized Kmt2d +/+ (wild-type) or Kmt2d −/− mice was analyzed for NP-specific IgM or IgG1 titer using the SBA Clonotyping System-HRP (SouthernBiotech). Plates were coated with 10 ug/ml NP(20)-BSA (Biosearch Technologies) and serum from immunized or nonimmunized mice was added to 96-well assay plates (Costar) at increasing dilutions in PBS with 1% BSA. Bound antibodies were detected with HRP-labeled goat anti-mouse IgG1 or IgM antibodies. The optical density of each well was measured at 405 nm.
In vitro class-switch recombination. For class switch recombination to IgG1, resting splenic B cells were isolated from 2.5-to 5-month-old Kmt2d +/+ CD19-Cre − (wild-type, 2 females and 3 males) and Kmt2d fl/fl CD19-Cre + (Kmt2d −/− ; 2 females and 3 males) mice by immunomagnetic depletion with anti-CD43 MicroBeads (anti-Ly48, Miltenyi Biotech), and cultured at 0.5 × 10 6 cells/ml with LPS (25 µg/ml; Sigma), IL-4 (5 ng/ml; Sigma) and RP105 (anti-mouse CD180; 0.5 µg/ml; BD Pharmingen) for 4 d. B cells were infected at 24 and 48 h in culture with pMX-Cre-IRES-GFP as described 37 to enhance Kmt2d fl/fl deletion. Class switching to IgG1 was measured at 96 h in the GFP + population (>90%) by flow cytometry using the following antibodies: IgG1-biotin (BD Pharmingen, clone A85-1 #553441) following streptavidin-Pacific Blue (Molecular Probes) and B220-Alexa700 (BioLegend, clone RA3 #103232). Data acquisition was performed on the BD LSR II Flow Cytometer (BD Biosciences) equipped with CellQuest software (Becton Dickinson). Analysis was performed with FlowJo software (Tree Star).
mRNA-seq library preparation and sequencing analysis. RNA was purified using the RNAeasy Plus Kit (QIAGEN) that included a genomic DNA elimination step. RNA size, concentration and integrity were verified using Agilent 2100 Bioanalyzer (Agilent Technologies). Libraries were generated using Illumina's TruSeq RNA sample Prep Kit v2, following the manufacurer's protocol. Sequencing of 8-10 pM of each library was done on the HiSeq2500 sequencer npg as 50-bp single-read runs. RNA-seq data from mouse B220 cells were aligned to the mm9 genome using STAR. RNA-seq data from FL subjects were aligned to the hg19 genome using TopHat. -2.0.10 with default parameters except -r 150 (TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions). Read counts were derived from HTSeq.scripts.count module in HTSeq-0.6.0 with default parameters (HTSeq-a Python framework to work with high-throughput sequencing data). Differentially expressed genes were generated by DESeq2-1.6.3 in R [moderated estimation of fold change and dispersion for RNA-seq data with DESeq2].
Human_Downregulated_Genes are downregulated genes (log fold change (log(FC)) < 0, p-val < 0.05, n = 519) in FL subjects with nonsense KMT2D mutations versus those with wild-type KMT2D, Fig. 3e ) based on RNA-seq data. Mouse_Downregulated_Genes were downregulated genes (log(FC) < 0, p-adjust < 0.1, Benjamini-Hochberg method, n = 1,016) in mouse B220 + cells, shKmt2d versus empty vector, Fig. 3f ) based on RNA-seq data. We also determined an RNA-seq leading-edge gene set (n = 347, Fig. 3i ). This gene set is the union of two gene subsets: (i) top 200 downregulated genes in Human_ Downregulated_Genes (ranked by logFC derived from B220 RNA-seq) and (ii) top 200 downregulated genes in Mouse_Downregulated_Genes (ranked by logFC derived from FL RNA-seq).
ChIP and ChIP-seq library preparation and sequencing analysis. H3K4me1 and H3K4me2 ChIP was performed as previously described 38 . Briefly, 4 ×10 6 mouse B220 + cells or DLBCL cells were fixed with 1% formaldehyde, lysed and sonicated (Branson Sonicator; Branson) leading to a DNA average size of 200 bp. 4 ul of H3K4me1 and H3K4me2-specific antibody (Abcam 32356 lot GR106705-5), tested for specificity by histone-peptide array (Active Motif 13001), was added to the precleared sample and incubated overnight at 4 °C. The complexes were purified using protein-A beads (Roche) followed by elution from the beads and reverse cross-linking. DNA was purified using PCR purification columns (QIAGEN).
H3K4me1 and H3K4me2 ChIP-seq libraries were prepared using 10 ng of DNA and Illumina's TruSeq ChIP sample prep, according to the manufacturer. Libraries were validated using the Agilent Technologies 2100 Bioanalyzer and Quant-iT dsDNA HS Assay (Life Technologies) and 8-10 pM was sequenced on a HiSeq2500 sequencer as 50-bp single-read runs. ChIP-seq data was aligned to the hg18 and hg19 genomes using STAR. Peak calling and read density in peak regions were performed by ChIPseeqer-2.1 with default parameters (an integrated ChIP-seq analysis platform with customizable workflows).
KMT2D ChIP assays were performed as previously described 39 . Briefly, 3-5 × 10 7 cells were cross-linked with 1% paraformaldehyde at room temperature for 15 min and sonicated to generate chromatin fragments of 200-600 bp. Fragmented chromatin was then immunoprecipitated overnight with inhouse-generated human KMT2D antibody specific for the N terminus previously described 5 , followed by washes and elution. ChIP-sequencing libraries were prepared with KAPA HTP ChIP-seq sample prep kit (KAPA Bioystems) for further high-throughput sequencing.
H3K4me1 and H3K4me2 ChIP DNA from OCI-LY7 cells transduced with KMT2D shRNA or empty vector control lentivirus were quantified by qPCR. Primers were designed to amplify loci with KMT2D peaks in OCI-LY7 and H3K4me1 and H3K4me2 depletion in OCI-LY1. Enrichment was calculated relative to input. The primers used were: TNFAIP3 (A20), Forward: GTGCTGCCATCCCCCAAATA, Reverse: AGCTTTCCCATGAGCCACT; SOCS3, Forward: ACCTGGCTAGACTGAGGTCAT, Reverse: TTAGAGG CGCTCTGGTTCCT; TRAF3, Forward: TCCAAGGGAAGATGAGGCCA, Reverse: CCTCGGGGGCCATAATACAG; SGK1, Forward: GACCGATTGGGA AAGCAGGT, Reverse: GAGTTGGCTCTGGCTTCCAT; IKBKB, Forward: AGGTCAACAAGGAGTCAGCC, Reverse: AGGAGGGAGGGGAGCTTTAT; TNS4 (negative control loci), Forward: TTATTTGGCTGGGTGTGGT, Reverse: GTAGAGACGGGATTTCACCATG.
For H3K4me1 and H3K4me2 ChIP data from mouse B220 + cells, candidate peaks were the union of the peaks called from each control replicate (n = 3) with ChIPseeqer. We defined peaks that overlapped with promoters (defined as ±2 kb windows centered on RefSeq transcription start sites (TSS)). Peaks that didn't overlap with promoters, gene bodies and exons were treated as enhancer peaks. Enhancer peaks inside gene bodies were identified as intragenic enhancer peaks. Intergenic enhancer peaks were defined as being within a 50-kb window from the corresponding genes. TSS Mouse_Enh_ H3K4 me1/me2 _Loss were genes identified with H3K4me1 and H3K4me2 depletion (>25% read density loss and P val < 0.05, t-test, n = 680) at enhancer peaks in shKmt2d (n = 3) (Fig. 4c,d) . We also determined a mouse H3K4me1-H3K4me2 ChIP-seq enhancer leading-edge gene set (n = 322, Fig. 4e) , which is the union of two gene subsets: (i) top 200 downregulated genes in Mouse_Enh_ H3K4 me1/me2 _Loss gene set (ranked by logFC derived from B220 RNA-seq) and (ii) top 200 downregulated genes in Mouse_Enh_H3K4 me1/me2 _Loss gene set (ranked by logFC derived from FL RNA-seq).
We derived Mouse_Pro_H3K4 me1/me2 _Loss gene sets (n = 602, Supplementary  Fig. 4e,f) and mouse H3K4me1 and H3K4me2 ChIP-seq promoter leading-edge genes (n = 321, Supplementary Fig. 4g ) in the same way as that for enhancers, described above.
For H3K4me1 and H3K4me2 ChIP data from OCI-LY1 and OCI-LY7 cell lines, candidate peaks were the union of the peaks called from two OCI-LY7 replicates (KMT2D WT) with ChIPseeqer. Promoter and enhancer peaks were determined by the same method described above for mouse B220 H3K4me1-H3K4me2 ChIPseq. In addition all enhancer peaks were overlapped with annotated enhancers previously determined in OCI-LY7. Human_ H3K4 me1/me2 _LOSS50 were genes with H3K4me1 and H3K4me2 depletion (>50% read density loss, n = 4416) in OCI-LY1 versus OCI-LY7 (Fig. 5b) .
KMT2D peaks from KMT2D ChIP-seq data were called using ChIPseeqer. Human_H3K4 me1/me2 _Loss50_KMT2D were genes with H3K4me1-H3K4me2 loss peaks (>50% read density loss and overlapped with KMT2D peaks, n = 1,248, Fig. 5d ). We chose 1,248 genes as leading-edge genes (ranked by H3K4me1-H3K4me2 loss from OCI-LY1 and OCI-LY7 ChIP-seq).
The code for performing these analyses will be made available upon request.
Gene ontology (GO) analysis with iPAGE. The GO analyses were performed with iPAGE 40 . The concept of mutual information (MI) 41 to directly quantify the dependency between expression and known pathways in MsigDB 42 or in the lymphoid signature database from the Staudt Lab 43 are used in iPAGE. Nonparametric statistical tests are then used to determine whether a pathway is significantly informative about the observed expression measurements. An iPAGE input file is defined across around 24,000 genes from Refseq genes, where each gene is associated with a unique expression status in our analysis. Meanwhile, each gene can be associated with a subset of M known pathways (for example, from the Gene Ontology annotations). For each pathway, the pathway profile is defined as binary vector with N elements, one for each gene. '1' indicates that the gene belongs to the pathway and '0' indicates that it does not. Given a pathway profile and an expression file with N e groups, iPAGE creates a table C of dimensions 2 × N e , in which C (1,j) represents the number of genes that are contained in the jth expression group and are also present in the given pathway. C (2,j) contains the number of genes that are in the jth expression group but not assigned to the pathway. Given this table, we calculate the empirical mutual information (MI) as follows: To assess the statistical significance of the calculated MI values, we used a nonparametric randomized-based statistical test. Given I as the real MI value and keeping the pathway profile unaltered, the expression file is shuffled 10,000 times and the corresponding MI values I random are calculated. A pathway is accepted only if I is larger than (1-max_p) of the I random values (max_p is set to 0.005). This corresponds to a P < 0.005. In iPAGE, pathways are first sorted by information (from informative to noninformative). Starting from the most informative pathways, the statistical test described above is applied to each pathway, and pathways that pass the test are returned. When 20 contiguous pathways in the sorted list do not pass the test, the procedure is stopped. Highly statistically significant mutual information is explained by combination of over-representation and under-representation in specific expression groups. To quantify the level of over-and under-representation, the hypergeometric distribution is used to calculate two distinct P values:
a. For over-representation: 
